Basel, 2017-04-04 - NBE-Therapeutics expands Board by Appointment of Hans-Peter Gerber

Hans-Peter Gerber, internationally renowned expert in ADC development and previously CSO of Pfizer's Bioconjugates Division joins the Board of Directors of NBE-Therapeutics

Read more

Basel, 2016-11-03 - NBE-Therapeutics raises CHF 20 million in Series B financing

NBE-Therapeutics announces closing of a CHF 20 Mio series B financing round led by PPF Group and existing investors of NBE

Read more

Copenhagen, Denmark, 2016-05-10 - NBE-Therapeutics had presented at BioEquity Conference Europe

Ulf Grawunder presented preclinical data of NBE's first lead ADC candidates NBE-001 and NBE-002 for multiple myeloma and breast cancer

Read more

Basel, 2016-01-05 - NBE-Therapeutics receives CHF 1.1 mio grant for collaboration with Zurich School for Applied Sciences

NBE-Therapeutics announces award of a CHF 1.1 Mio grant from the Swiss Commission for Technology and Innovation (CTI) for a collaboration with the group of Prof. Zaborosch at Zurich School of Applied Sciences (ZHAW), Wädenswil, Switzerland

Read more

next >